Literature DB >> 33954808

Reconversion to ventriculoperitoneal shunt following ventriculoatrial shunt malfunction in children.

Shota Yamashita1, Tomomi Kimiwada2, Toshiaki Hayashi1, Reizo Shirane1, Teiji Tomonaga3.   

Abstract

PURPOSE: To analyze the long-term efficacy of the ventriculoatrial shunt (VAS) in pediatric patients with hydrocephalus, focusing on the atrial catheter and suitable revision procedures of the distal catheter following VAS malformation performed at our institution.
METHODS: The authors retrospectively analyzed data of 28 pediatric patients under the age of 10 years who were treated with VAS for hydrocephalus and who had a follow-up period of at least 5 years.
RESULTS: A total of 42 atrial tube revision procedures were performed in 28 patients during the study period. The median atrial tube survival time due to atrial tube obstruction was 2.32 years (n = 31, range: 0.4-8.08 years). Atrial tube survival time was shorter in younger children (p < 0.0001) and in children who were shorter in height (p = 0.0001). As a revision procedure following atrial tube malfunction, 22 (78.6%) out of the 28 patients who had an inserted VAS had the VAS reconversion into a VPS at the last follow-up.
CONCLUSIONS: VAS can be a useful alternative to VPS, but it requires frequent atrial tube revisions, especially in younger children. Reconversion to VPS after VAS malfunction is a reasonable option and is associated with longer shunt survival time despite its previously observed difficulties.

Entities:  

Keywords:  Children; Hydrocephalus; Ventriculoatrial shunt; Ventriculoperitoneal shunt

Year:  2021        PMID: 33954808     DOI: 10.1007/s00381-021-05045-7

Source DB:  PubMed          Journal:  Childs Nerv Syst        ISSN: 0256-7040            Impact factor:   1.475


  1 in total

1.  Ascites and abdominal pseudocysts following ventriculoperitoneal shunt surgery: variations of the same theme.

Authors:  Rajeev Kariyattil; Paul Steinbok; Ashutosh Singhal; D Douglas Cochrane
Journal:  J Neurosurg       Date:  2007-05       Impact factor: 5.115

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.